The Experts below are selected from a list of 87 Experts worldwide ranked by ideXlab platform

K. Komlos - One of the best experts on this subject based on the ideXlab platform.

  • Discovery and diagnosis of metastatic colorectal cancer (mCRC) in the real world: Final results from a European survey
    Annals of Oncology, 2019
    Co-Authors: I.m. Rawicka, Z. Maravic, L. Lemmens, A. Benedict, K. Komlos, P. Rakonczai
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancers patient organisation, planned and carried out an international survey on the Unmet Needs of Patients Living with mCRC. The aim was to better understand the challenges, needs, and health-related quality of life (HRQoL) of those living with mCRC in 15 European countries. Methods Nurses and clinicians together with DiCE partner organisations recruited patients to fill in the survey (online or paper). Data collected included information on demographics, the disease discovery, diagnosis and treatment and support received. Questions on discovery and diagnoses covered reasons for contacting physicians, symptoms experience, the lag time between first symptoms and seeking clinical help, and misdiagnosis. Single Data Entry from paper surveys was executed by DiCE. Data were analyzed descriptively. Results 883 surveys were collected and analyzed: Austria (8), Belgium (65), Cyprus (57), Hungary (103), Ireland (3), Italy (36), Germany (22), Netherlands (40), Norway (1), Poland (163), Portugal (24), Serbia (170), Spain (112), Turkey (26) and the UK (53). Item completion rates were high. Mean time with mCRC was 2yrs. Diagnosis was established at a routine visit for 20%; at visits due to CRC-related or non-CRC related symptoms (41% and 26%); or at emergency hospitalization (19%); with only 5% through screening. CRC symptom awareness was very low: on average only 28% of patients knew before what symptoms CRC may present. Although 39% of patients waited Conclusions Awareness of patients with CRC is low, with few respondents recognising symptoms and seeking help without delay. Misdiagnosis levels are still high. Despite the existence of various screening in surveyed countries, awareness and compliance rates are low. The conditions of the discovery of mCRC need to be improved both on the patient awareness and the clinical side. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

  • Quality of life (QoL) in metastatic colorectal cancer (mCRC) in the real world: Final results of a European survey
    Annals of Oncology, 2019
    Co-Authors: Z. Maravic, I.m. Rawicka, L. Lemmens, A. Benedict, P. Rakonczai, K. Komlos
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancer patients umbrella organization, planned and executed a cross-sectional survey in 15 European countries on the Unmet Needs of Patients Living with mCRC to examine the challenges and needs and QoL of those living with mCRC. Methods DiCE partner organisations, together with clinicians and nurses recruited patients for the survey (paper-based and online). The survey included demographics, Data on discovery of the disease, diagnosis and treatment and the EORTC QLQ-C30 and CR29. Single Data Entry from the paper surveys was done by DiCE. Descriptive statistics and regression analyses were run to examine the global QoL score, function (F) - and symptom-specific scores, the item on financial difficulties and CR29 scores and their association with patient and disease characteristics and care setting by country and overall. Results 883 surveys from Austria, Belgium, Cyprus (CY), Germany, Hungary (HU), Italy, Netherlands (NL), Norway, Serbia (RS), Poland, Spain (SP), UK, Portugal, Turkey and Ireland were collected. Only 8 countries with samples over 35 were analyzed on their own. Completion rates across QoL items were high (91-94%). Large variation across countries have been observed in mean scores (Table). Eastern vs Western Europe contrasted sharply, with Serbia and Poland reporting lower functional and much higher symptom scores for fatigue, nausea, vomiting, pain and insomnia. Regression analyses indicated that after adjustment for age, gender and care setting country differences remained significant. Patterns in results across dimensions of EORTC QLQ-CR29 were similar. Table . 659P Mean (SD) Global QoL Physical F Role F Emotional F Cognitive F Social F Lowest score 55.94 (21.10) RS 69.06 (23.93) CY 62.58 (34.73) CY 53.51 (28.35) RS 71.31 (24.6) RS 54.04 (25.91) RS Highest score 69.26 (20.68) HU 84.29 (17.87) SP 81.76 (25.41) SP 80.92 (21.04) NL 87.86 (19.13) HU 80.91 (24.63) HU OVERALL 62.02 (21.75) 74.25 (20.85) 71.41 (28.76) 68.25 (26.41) 78.58 (23.39) 68.56 (28.99) Conclusions Country specific mean QoL scores in all function/symptom dimensions varied greatly across countries. This study indicates that care setting and other country-specific circumstances have important associations to QoL. Real-world mCRC patients’ QoL may be lower than those recruited in clinical trials. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

P. Rakonczai - One of the best experts on this subject based on the ideXlab platform.

  • Discovery and diagnosis of metastatic colorectal cancer (mCRC) in the real world: Final results from a European survey
    Annals of Oncology, 2019
    Co-Authors: I.m. Rawicka, Z. Maravic, L. Lemmens, A. Benedict, K. Komlos, P. Rakonczai
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancers patient organisation, planned and carried out an international survey on the Unmet Needs of Patients Living with mCRC. The aim was to better understand the challenges, needs, and health-related quality of life (HRQoL) of those living with mCRC in 15 European countries. Methods Nurses and clinicians together with DiCE partner organisations recruited patients to fill in the survey (online or paper). Data collected included information on demographics, the disease discovery, diagnosis and treatment and support received. Questions on discovery and diagnoses covered reasons for contacting physicians, symptoms experience, the lag time between first symptoms and seeking clinical help, and misdiagnosis. Single Data Entry from paper surveys was executed by DiCE. Data were analyzed descriptively. Results 883 surveys were collected and analyzed: Austria (8), Belgium (65), Cyprus (57), Hungary (103), Ireland (3), Italy (36), Germany (22), Netherlands (40), Norway (1), Poland (163), Portugal (24), Serbia (170), Spain (112), Turkey (26) and the UK (53). Item completion rates were high. Mean time with mCRC was 2yrs. Diagnosis was established at a routine visit for 20%; at visits due to CRC-related or non-CRC related symptoms (41% and 26%); or at emergency hospitalization (19%); with only 5% through screening. CRC symptom awareness was very low: on average only 28% of patients knew before what symptoms CRC may present. Although 39% of patients waited Conclusions Awareness of patients with CRC is low, with few respondents recognising symptoms and seeking help without delay. Misdiagnosis levels are still high. Despite the existence of various screening in surveyed countries, awareness and compliance rates are low. The conditions of the discovery of mCRC need to be improved both on the patient awareness and the clinical side. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

  • Quality of life (QoL) in metastatic colorectal cancer (mCRC) in the real world: Final results of a European survey
    Annals of Oncology, 2019
    Co-Authors: Z. Maravic, I.m. Rawicka, L. Lemmens, A. Benedict, P. Rakonczai, K. Komlos
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancer patients umbrella organization, planned and executed a cross-sectional survey in 15 European countries on the Unmet Needs of Patients Living with mCRC to examine the challenges and needs and QoL of those living with mCRC. Methods DiCE partner organisations, together with clinicians and nurses recruited patients for the survey (paper-based and online). The survey included demographics, Data on discovery of the disease, diagnosis and treatment and the EORTC QLQ-C30 and CR29. Single Data Entry from the paper surveys was done by DiCE. Descriptive statistics and regression analyses were run to examine the global QoL score, function (F) - and symptom-specific scores, the item on financial difficulties and CR29 scores and their association with patient and disease characteristics and care setting by country and overall. Results 883 surveys from Austria, Belgium, Cyprus (CY), Germany, Hungary (HU), Italy, Netherlands (NL), Norway, Serbia (RS), Poland, Spain (SP), UK, Portugal, Turkey and Ireland were collected. Only 8 countries with samples over 35 were analyzed on their own. Completion rates across QoL items were high (91-94%). Large variation across countries have been observed in mean scores (Table). Eastern vs Western Europe contrasted sharply, with Serbia and Poland reporting lower functional and much higher symptom scores for fatigue, nausea, vomiting, pain and insomnia. Regression analyses indicated that after adjustment for age, gender and care setting country differences remained significant. Patterns in results across dimensions of EORTC QLQ-CR29 were similar. Table . 659P Mean (SD) Global QoL Physical F Role F Emotional F Cognitive F Social F Lowest score 55.94 (21.10) RS 69.06 (23.93) CY 62.58 (34.73) CY 53.51 (28.35) RS 71.31 (24.6) RS 54.04 (25.91) RS Highest score 69.26 (20.68) HU 84.29 (17.87) SP 81.76 (25.41) SP 80.92 (21.04) NL 87.86 (19.13) HU 80.91 (24.63) HU OVERALL 62.02 (21.75) 74.25 (20.85) 71.41 (28.76) 68.25 (26.41) 78.58 (23.39) 68.56 (28.99) Conclusions Country specific mean QoL scores in all function/symptom dimensions varied greatly across countries. This study indicates that care setting and other country-specific circumstances have important associations to QoL. Real-world mCRC patients’ QoL may be lower than those recruited in clinical trials. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

Z. Maravic - One of the best experts on this subject based on the ideXlab platform.

  • Discovery and diagnosis of metastatic colorectal cancer (mCRC) in the real world: Final results from a European survey
    Annals of Oncology, 2019
    Co-Authors: I.m. Rawicka, Z. Maravic, L. Lemmens, A. Benedict, K. Komlos, P. Rakonczai
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancers patient organisation, planned and carried out an international survey on the Unmet Needs of Patients Living with mCRC. The aim was to better understand the challenges, needs, and health-related quality of life (HRQoL) of those living with mCRC in 15 European countries. Methods Nurses and clinicians together with DiCE partner organisations recruited patients to fill in the survey (online or paper). Data collected included information on demographics, the disease discovery, diagnosis and treatment and support received. Questions on discovery and diagnoses covered reasons for contacting physicians, symptoms experience, the lag time between first symptoms and seeking clinical help, and misdiagnosis. Single Data Entry from paper surveys was executed by DiCE. Data were analyzed descriptively. Results 883 surveys were collected and analyzed: Austria (8), Belgium (65), Cyprus (57), Hungary (103), Ireland (3), Italy (36), Germany (22), Netherlands (40), Norway (1), Poland (163), Portugal (24), Serbia (170), Spain (112), Turkey (26) and the UK (53). Item completion rates were high. Mean time with mCRC was 2yrs. Diagnosis was established at a routine visit for 20%; at visits due to CRC-related or non-CRC related symptoms (41% and 26%); or at emergency hospitalization (19%); with only 5% through screening. CRC symptom awareness was very low: on average only 28% of patients knew before what symptoms CRC may present. Although 39% of patients waited Conclusions Awareness of patients with CRC is low, with few respondents recognising symptoms and seeking help without delay. Misdiagnosis levels are still high. Despite the existence of various screening in surveyed countries, awareness and compliance rates are low. The conditions of the discovery of mCRC need to be improved both on the patient awareness and the clinical side. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

  • Quality of life (QoL) in metastatic colorectal cancer (mCRC) in the real world: Final results of a European survey
    Annals of Oncology, 2019
    Co-Authors: Z. Maravic, I.m. Rawicka, L. Lemmens, A. Benedict, P. Rakonczai, K. Komlos
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancer patients umbrella organization, planned and executed a cross-sectional survey in 15 European countries on the Unmet Needs of Patients Living with mCRC to examine the challenges and needs and QoL of those living with mCRC. Methods DiCE partner organisations, together with clinicians and nurses recruited patients for the survey (paper-based and online). The survey included demographics, Data on discovery of the disease, diagnosis and treatment and the EORTC QLQ-C30 and CR29. Single Data Entry from the paper surveys was done by DiCE. Descriptive statistics and regression analyses were run to examine the global QoL score, function (F) - and symptom-specific scores, the item on financial difficulties and CR29 scores and their association with patient and disease characteristics and care setting by country and overall. Results 883 surveys from Austria, Belgium, Cyprus (CY), Germany, Hungary (HU), Italy, Netherlands (NL), Norway, Serbia (RS), Poland, Spain (SP), UK, Portugal, Turkey and Ireland were collected. Only 8 countries with samples over 35 were analyzed on their own. Completion rates across QoL items were high (91-94%). Large variation across countries have been observed in mean scores (Table). Eastern vs Western Europe contrasted sharply, with Serbia and Poland reporting lower functional and much higher symptom scores for fatigue, nausea, vomiting, pain and insomnia. Regression analyses indicated that after adjustment for age, gender and care setting country differences remained significant. Patterns in results across dimensions of EORTC QLQ-CR29 were similar. Table . 659P Mean (SD) Global QoL Physical F Role F Emotional F Cognitive F Social F Lowest score 55.94 (21.10) RS 69.06 (23.93) CY 62.58 (34.73) CY 53.51 (28.35) RS 71.31 (24.6) RS 54.04 (25.91) RS Highest score 69.26 (20.68) HU 84.29 (17.87) SP 81.76 (25.41) SP 80.92 (21.04) NL 87.86 (19.13) HU 80.91 (24.63) HU OVERALL 62.02 (21.75) 74.25 (20.85) 71.41 (28.76) 68.25 (26.41) 78.58 (23.39) 68.56 (28.99) Conclusions Country specific mean QoL scores in all function/symptom dimensions varied greatly across countries. This study indicates that care setting and other country-specific circumstances have important associations to QoL. Real-world mCRC patients’ QoL may be lower than those recruited in clinical trials. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

I.m. Rawicka - One of the best experts on this subject based on the ideXlab platform.

  • Discovery and diagnosis of metastatic colorectal cancer (mCRC) in the real world: Final results from a European survey
    Annals of Oncology, 2019
    Co-Authors: I.m. Rawicka, Z. Maravic, L. Lemmens, A. Benedict, K. Komlos, P. Rakonczai
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancers patient organisation, planned and carried out an international survey on the Unmet Needs of Patients Living with mCRC. The aim was to better understand the challenges, needs, and health-related quality of life (HRQoL) of those living with mCRC in 15 European countries. Methods Nurses and clinicians together with DiCE partner organisations recruited patients to fill in the survey (online or paper). Data collected included information on demographics, the disease discovery, diagnosis and treatment and support received. Questions on discovery and diagnoses covered reasons for contacting physicians, symptoms experience, the lag time between first symptoms and seeking clinical help, and misdiagnosis. Single Data Entry from paper surveys was executed by DiCE. Data were analyzed descriptively. Results 883 surveys were collected and analyzed: Austria (8), Belgium (65), Cyprus (57), Hungary (103), Ireland (3), Italy (36), Germany (22), Netherlands (40), Norway (1), Poland (163), Portugal (24), Serbia (170), Spain (112), Turkey (26) and the UK (53). Item completion rates were high. Mean time with mCRC was 2yrs. Diagnosis was established at a routine visit for 20%; at visits due to CRC-related or non-CRC related symptoms (41% and 26%); or at emergency hospitalization (19%); with only 5% through screening. CRC symptom awareness was very low: on average only 28% of patients knew before what symptoms CRC may present. Although 39% of patients waited Conclusions Awareness of patients with CRC is low, with few respondents recognising symptoms and seeking help without delay. Misdiagnosis levels are still high. Despite the existence of various screening in surveyed countries, awareness and compliance rates are low. The conditions of the discovery of mCRC need to be improved both on the patient awareness and the clinical side. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

  • Quality of life (QoL) in metastatic colorectal cancer (mCRC) in the real world: Final results of a European survey
    Annals of Oncology, 2019
    Co-Authors: Z. Maravic, I.m. Rawicka, L. Lemmens, A. Benedict, P. Rakonczai, K. Komlos
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancer patients umbrella organization, planned and executed a cross-sectional survey in 15 European countries on the Unmet Needs of Patients Living with mCRC to examine the challenges and needs and QoL of those living with mCRC. Methods DiCE partner organisations, together with clinicians and nurses recruited patients for the survey (paper-based and online). The survey included demographics, Data on discovery of the disease, diagnosis and treatment and the EORTC QLQ-C30 and CR29. Single Data Entry from the paper surveys was done by DiCE. Descriptive statistics and regression analyses were run to examine the global QoL score, function (F) - and symptom-specific scores, the item on financial difficulties and CR29 scores and their association with patient and disease characteristics and care setting by country and overall. Results 883 surveys from Austria, Belgium, Cyprus (CY), Germany, Hungary (HU), Italy, Netherlands (NL), Norway, Serbia (RS), Poland, Spain (SP), UK, Portugal, Turkey and Ireland were collected. Only 8 countries with samples over 35 were analyzed on their own. Completion rates across QoL items were high (91-94%). Large variation across countries have been observed in mean scores (Table). Eastern vs Western Europe contrasted sharply, with Serbia and Poland reporting lower functional and much higher symptom scores for fatigue, nausea, vomiting, pain and insomnia. Regression analyses indicated that after adjustment for age, gender and care setting country differences remained significant. Patterns in results across dimensions of EORTC QLQ-CR29 were similar. Table . 659P Mean (SD) Global QoL Physical F Role F Emotional F Cognitive F Social F Lowest score 55.94 (21.10) RS 69.06 (23.93) CY 62.58 (34.73) CY 53.51 (28.35) RS 71.31 (24.6) RS 54.04 (25.91) RS Highest score 69.26 (20.68) HU 84.29 (17.87) SP 81.76 (25.41) SP 80.92 (21.04) NL 87.86 (19.13) HU 80.91 (24.63) HU OVERALL 62.02 (21.75) 74.25 (20.85) 71.41 (28.76) 68.25 (26.41) 78.58 (23.39) 68.56 (28.99) Conclusions Country specific mean QoL scores in all function/symptom dimensions varied greatly across countries. This study indicates that care setting and other country-specific circumstances have important associations to QoL. Real-world mCRC patients’ QoL may be lower than those recruited in clinical trials. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

A. Benedict - One of the best experts on this subject based on the ideXlab platform.

  • Discovery and diagnosis of metastatic colorectal cancer (mCRC) in the real world: Final results from a European survey
    Annals of Oncology, 2019
    Co-Authors: I.m. Rawicka, Z. Maravic, L. Lemmens, A. Benedict, K. Komlos, P. Rakonczai
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancers patient organisation, planned and carried out an international survey on the Unmet Needs of Patients Living with mCRC. The aim was to better understand the challenges, needs, and health-related quality of life (HRQoL) of those living with mCRC in 15 European countries. Methods Nurses and clinicians together with DiCE partner organisations recruited patients to fill in the survey (online or paper). Data collected included information on demographics, the disease discovery, diagnosis and treatment and support received. Questions on discovery and diagnoses covered reasons for contacting physicians, symptoms experience, the lag time between first symptoms and seeking clinical help, and misdiagnosis. Single Data Entry from paper surveys was executed by DiCE. Data were analyzed descriptively. Results 883 surveys were collected and analyzed: Austria (8), Belgium (65), Cyprus (57), Hungary (103), Ireland (3), Italy (36), Germany (22), Netherlands (40), Norway (1), Poland (163), Portugal (24), Serbia (170), Spain (112), Turkey (26) and the UK (53). Item completion rates were high. Mean time with mCRC was 2yrs. Diagnosis was established at a routine visit for 20%; at visits due to CRC-related or non-CRC related symptoms (41% and 26%); or at emergency hospitalization (19%); with only 5% through screening. CRC symptom awareness was very low: on average only 28% of patients knew before what symptoms CRC may present. Although 39% of patients waited Conclusions Awareness of patients with CRC is low, with few respondents recognising symptoms and seeking help without delay. Misdiagnosis levels are still high. Despite the existence of various screening in surveyed countries, awareness and compliance rates are low. The conditions of the discovery of mCRC need to be improved both on the patient awareness and the clinical side. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.

  • Quality of life (QoL) in metastatic colorectal cancer (mCRC) in the real world: Final results of a European survey
    Annals of Oncology, 2019
    Co-Authors: Z. Maravic, I.m. Rawicka, L. Lemmens, A. Benedict, P. Rakonczai, K. Komlos
    Abstract:

    Abstract Background Digestive Cancers Europe (DiCE), a European digestive cancer patients umbrella organization, planned and executed a cross-sectional survey in 15 European countries on the Unmet Needs of Patients Living with mCRC to examine the challenges and needs and QoL of those living with mCRC. Methods DiCE partner organisations, together with clinicians and nurses recruited patients for the survey (paper-based and online). The survey included demographics, Data on discovery of the disease, diagnosis and treatment and the EORTC QLQ-C30 and CR29. Single Data Entry from the paper surveys was done by DiCE. Descriptive statistics and regression analyses were run to examine the global QoL score, function (F) - and symptom-specific scores, the item on financial difficulties and CR29 scores and their association with patient and disease characteristics and care setting by country and overall. Results 883 surveys from Austria, Belgium, Cyprus (CY), Germany, Hungary (HU), Italy, Netherlands (NL), Norway, Serbia (RS), Poland, Spain (SP), UK, Portugal, Turkey and Ireland were collected. Only 8 countries with samples over 35 were analyzed on their own. Completion rates across QoL items were high (91-94%). Large variation across countries have been observed in mean scores (Table). Eastern vs Western Europe contrasted sharply, with Serbia and Poland reporting lower functional and much higher symptom scores for fatigue, nausea, vomiting, pain and insomnia. Regression analyses indicated that after adjustment for age, gender and care setting country differences remained significant. Patterns in results across dimensions of EORTC QLQ-CR29 were similar. Table . 659P Mean (SD) Global QoL Physical F Role F Emotional F Cognitive F Social F Lowest score 55.94 (21.10) RS 69.06 (23.93) CY 62.58 (34.73) CY 53.51 (28.35) RS 71.31 (24.6) RS 54.04 (25.91) RS Highest score 69.26 (20.68) HU 84.29 (17.87) SP 81.76 (25.41) SP 80.92 (21.04) NL 87.86 (19.13) HU 80.91 (24.63) HU OVERALL 62.02 (21.75) 74.25 (20.85) 71.41 (28.76) 68.25 (26.41) 78.58 (23.39) 68.56 (28.99) Conclusions Country specific mean QoL scores in all function/symptom dimensions varied greatly across countries. This study indicates that care setting and other country-specific circumstances have important associations to QoL. Real-world mCRC patients’ QoL may be lower than those recruited in clinical trials. Legal entity responsible for the study EuropaColon / Digestive Cancers Europe. Funding Merck, BMS, Sandoz and Sirtex. Disclosure All authors have declared no conflicts of interest.